Eli Lilly and Co. today announced that it will proceed with its first Phase III trial on Alzheimer's patients, for its experimental treatment LY450139, which is designed to prevent an enzyme from producing amyloid beta.
Published in Brief:
Attest Health Care Advisors
|Biotechnology/Pharmaceutical Patent Attorney||
Coats and Bennett PLLC
|Sr. Regulatory Specialist, Biotech Center of Expertise||
BASF, The Chemical Co.
|San Diego, CA|
Meridian Health Plan